Diaceutics PLC
Symboli: DIUXF
PNK
1.3672
USDMarkkinahinta tänään
-124.8659
P/E-suhde
2.7906
PEG-suhde
123.70M
MRK Cap
- 0.00%
DIV Tuotto
Diaceutics PLC (DIUXF) Tilinpäätöstiedotteet
Tase
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 19.8 | 19.7 | 25.3 | |||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.net-receivables | 0 | 10.4 | 10 | 7.8 | |||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.other-current-assets | 0 | 0.6 | 0.4 | 0.6 | |||||||
balance-sheet.row.total-current-assets | 0 | 30.9 | 30.1 | 33.6 | |||||||
balance-sheet.row.property-plant-equipment-net | 0 | 2.1 | 2.1 | 0.2 | |||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.intangible-assets | 0 | 15.2 | 12.8 | 9.4 | |||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 15.2 | 12.8 | 9.4 | |||||||
balance-sheet.row.long-term-investments | 0 | 17.1 | 14.7 | 9.2 | |||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0.3 | |||||||
balance-sheet.row.other-non-current-assets | 0 | -17.1 | -14.7 | -9.2 | |||||||
balance-sheet.row.total-non-current-assets | 0 | 17.4 | 15 | 9.9 | |||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-assets | 0 | 48.3 | 45 | 43.5 | |||||||
balance-sheet.row.account-payables | 0 | 0.8 | 0.5 | 0.5 | |||||||
balance-sheet.row.short-term-debt | 0 | 0.1 | 0.3 | 0.1 | |||||||
balance-sheet.row.tax-payables | 0 | 0.4 | 0.3 | 0.8 | |||||||
balance-sheet.row.long-term-debt-total | 0 | 1.2 | 1.3 | 0 | |||||||
Deferred Revenue Non Current | 0 | 0 | -0.4 | 0 | |||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||
balance-sheet.row.other-current-liab | 0 | 2.5 | 1.6 | 2 | |||||||
balance-sheet.row.total-non-current-liabilities | 0 | 2 | 1.7 | 0.4 | |||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.capital-lease-obligations | 0 | 1.3 | 1.4 | 0 | |||||||
balance-sheet.row.total-liab | 0 | 5.7 | 4.4 | 3.3 | |||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0.3 | 0 | |||||||
balance-sheet.row.common-stock | 0 | 0.2 | 0.2 | 0.2 | |||||||
balance-sheet.row.retained-earnings | 0 | 5.3 | 4.1 | 3.2 | |||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0.1 | -0.3 | 0 | |||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 36.9 | 36.4 | 36.9 | |||||||
balance-sheet.row.total-stockholders-equity | 0 | 42.5 | 40.6 | 40.2 | |||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 48.3 | 45 | 43.5 | |||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-equity | 0 | 42.5 | 40.6 | 40.2 | |||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||
Total Investments | 0 | 17.1 | 14.7 | 9.2 | |||||||
balance-sheet.row.total-debt | 0 | 1.3 | 1.6 | 0.1 | |||||||
balance-sheet.row.net-debt | 0 | -18.5 | -18.1 | -25.1 |
Kassavirtalaskelma
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 0.6 | 0.5 | -0.7 | |||||||
cash-flows.row.depreciation-and-amortization | 0 | 3 | 1.8 | 0.8 | |||||||
cash-flows.row.deferred-income-tax | 0 | 1.3 | -0.5 | -0.7 | |||||||
cash-flows.row.stock-based-compensation | 0 | 0.5 | 0.4 | 0.3 | |||||||
cash-flows.row.change-in-working-capital | 0 | -0.3 | -1.7 | 0.5 | |||||||
cash-flows.row.account-receivables | 0 | -1.6 | -1.5 | 0.5 | |||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.account-payables | 0 | 1.3 | -0.2 | -0.1 | |||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.other-non-cash-items | 0 | 0 | 0.1 | 0 | |||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -4.9 | -5.6 | -6.3 | |||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.other-investing-activites | 0 | 0.1 | 0 | 0 | |||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -4.8 | -5.6 | -6.3 | |||||||
cash-flows.row.debt-repayment | 0 | 0 | -0.1 | 0 | |||||||
cash-flows.row.common-stock-issued | 0 | 0.1 | 0 | 19.6 | |||||||
cash-flows.row.common-stock-repurchased | 0 | -0.1 | -0.2 | 0 | |||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.other-financing-activites | 0 | -0.2 | 0 | 0 | |||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -0.2 | -0.3 | 19.6 | |||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | -0.3 | 0 | |||||||
cash-flows.row.net-change-in-cash | 0 | 0.2 | -5.6 | 13.5 | |||||||
cash-flows.row.cash-at-end-of-period | 0 | 19.8 | 19.7 | 25.3 | |||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 19.7 | 25.3 | 11.7 | |||||||
cash-flows.row.operating-cash-flow | 0 | 5.1 | 0.6 | 0.3 | |||||||
cash-flows.row.capital-expenditure | 0 | -4.9 | -5.6 | -6.3 | |||||||
cash-flows.row.free-cash-flow | 0 | 0.2 | -5 | -6 |
Tuloslaskelmarivi
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 19.5 | 13.9 | 12.7 | |||||||
income-statement-row.row.cost-of-revenue | 0 | 2.8 | 3.2 | 3.2 | |||||||
income-statement-row.row.gross-profit | 0 | 16.7 | 10.7 | 9.5 | |||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.operating-expenses | 0 | 16.2 | 10.2 | 9.7 | |||||||
income-statement-row.row.cost-and-expenses | 0 | 18.9 | 13.4 | 13 | |||||||
income-statement-row.row.interest-income | 0 | 0.1 | 0.1 | 0 | |||||||
income-statement-row.row.interest-expense | 0 | 0.1 | 0.1 | 0 | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.total-other-income-expensenet | 0 | 0 | -0.1 | 0 | |||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.total-operating-expenses | 0 | 0 | -0.1 | 0 | |||||||
income-statement-row.row.interest-expense | 0 | 0.1 | 0.1 | 0 | |||||||
income-statement-row.row.depreciation-and-amortization | 0 | 3 | 1.8 | 0.8 | |||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||
income-statement-row.row.operating-income | 0 | 0.6 | 0.6 | -0.7 | |||||||
income-statement-row.row.income-before-tax | 0 | 0.6 | 0.5 | -0.7 | |||||||
income-statement-row.row.income-tax-expense | 0 | -0.2 | -0.1 | -0.9 | |||||||
income-statement-row.row.net-income | 0 | 0.7 | 0.6 | 0.3 |
Usein kysytty kysymys
Mikä on Diaceutics PLC (DIUXF) taseen loppusumma?
Diaceutics PLC (DIUXF) kokonaisvarat ovat 48256000.000.
Mikä on yrityksen vuotuinen liikevaihto?
Vuotuinen liikevaihto on N/A.
Mikä on yrityksen voittomarginaali?
Yrityksen voittomarginaali on 0.796.
Mikä on yrityksen vapaa kassavirta?
Vapaa kassavirta on -0.027.
Mikä on yrityksen nettovoittomarginaali?
Nettovoittomarginaali on -0.027.
Mikä on yrityksen kokonaistulot?
Kokonaisliikevaihto on -0.061.
Mikä on Diaceutics PLC (DIUXF) nettovoitto (nettotulos)?
Nettovoitto (nettotulos) on 724000.000.
Mikä on yrityksen kokonaisvelka?
Kokonaisvelka on 1329000.000.
Mikä on yrityksen toimintakulujen määrä?
Toimintakulut ovat 16166000.000.
Mikä on yrityksen kassan määrä?
Yrityksen kassavarat ovat 0.000.